Ambroxol Hydrochloride/Amoxicillin

This study aims to study the comparative pharmacokinetics of amoxicillin and ambroxol tablets (each tablet contains 250 mg amoxicillin and 15 mg ambroxol hydrochloride) developed and produced by Beijing Guolian Chenghui Pharmaceutical Technology Co., Ltd. and amoxicillin tablets and ambroxol hydrochloride tablets in healthy subjects, so as to examine whether the absorption degree and speed of the two main drugs after the combination are not inferior to those of the two single drugs.

The purpose of this study is to study the relative bioavailability of the dry mixed suspension (each bag contains 125 mg amoxicillin and 7.5 mg ambroxol hydrochloride) and amoxicillin ambroxol capsules (each capsule contains 250 mg amoxicillin and 15 mg ambroxol hydrochloride) developed and produced by Beijing Guolian Chenghui Pharmaceutical Technology Co., Ltd. in healthy humans, and to provide a basis for whether they are bioequivalent to the amoxicillin ambroxol tablets produced by the company.